Novan (NASDAQ:NOVN) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report released on Sunday.
Several other equities research analysts have also recently weighed in on NOVN. Wedbush reaffirmed a “neutral” rating and issued a $6.00 price target on shares of Novan in a research report on Monday, September 25th. Zacks Investment Research raised shares of Novan from a “sell” rating to a “hold” rating in a research report on Wednesday, October 4th.
Shares of Novan (NASDAQ NOVN) traded down $0.18 on Friday, hitting $4.22. 107,100 shares of the stock traded hands, compared to its average volume of 209,243. Novan has a 52-week low of $3.52 and a 52-week high of $27.76. The stock has a market cap of $67.48, a PE ratio of -0.53 and a beta of 5.15.
Novan, Inc is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Novan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novan and related companies with MarketBeat.com's FREE daily email newsletter.